The technology transfer arm of the University of Maryland has entered into separate licensing agreements with two Baltimore companies aiming to bring anti-cancer therapies to market.
The first agreement by University of Maryland Ventures grants Educational and Scientific LLC the licensing rights to its interest in a molecule whose anti-cancer properties were jointly discovered by the company and the University of Maryland Baltimore.
The plant-derived molecule has potential for treatment of lung, Non-Hodgkin’s lymphoma, pancreatic and prostate cancer, said officials from the university and the company, lead by Henry Lowe, a medicinal chemist and adjunct professor of medicine in the university's school of medicine.
The second agreement gives the start-up Glycocept Inc. the licensing rights to technology invented at the university in the lab of Eric J. Sundberg, associate professor of medicine in Maryland’s school of medicine and co-director of the division of basic science in the Institute of Human Virology.
The technology can boost the efficacy of therapeutic monoclonal antibodies, which normally fight cancer by binding to diseased cells and stimulating the immune system to attack those cells.
Details of the licensing agreements were not disclosed.